SillaJen, Transgene fall with latest oncolytic virus setback

The failure of Pexa-Vec from Transgene and SillaJen in a Phase III study is the latest blow to the oncolytic virus field, but it may say less about the modality as a whole than about the virus' specific construct and trial design.

SillaJen Inc. (KOSDAQ:215600), which holds North American rights to Pexa-Vec, will likely

Read the full 545 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE